Subtopic Deep Dive

← Amyloidosis: Diagnosis, Treatment, Outcomes

RNAi Therapy for Transthyretin Amyloidosis
Research Guide

What is RNAi Therapy for Transthyretin Amyloidosis?

RNAi therapy for transthyretin amyloidosis uses RNA interference to silence the TTR gene, reducing transthyretin protein production in hereditary ATTR amyloidosis (hATTR).

Patisiran, an RNAi therapeutic, showed efficacy in the APOLLO trial by improving neuropathy and cardiac outcomes in hATTR patients (Adams et al., 2018, 2745 citations). Vutrisiran and inotersen provide similar TTR lowering with phase II/III data (Suhr et al., 2015, 316 citations; Benson et al., 2018, 1352 citations). Over 20 clinical papers track long-term safety and polyneuropathy stabilization.

Curated Papers

Key Challenges

Why It Matters

Patisiran reduced TTR by 80% and halted neuropathy progression in APOLLO, enabling first disease-modifying treatment for hATTR polyneuropathy (Adams et al., 2018). Inotersen improved quality of life despite thrombocytopenia risks, expanding options for familial amyloidotic polyneuropathy (Benson et al., 2018). These therapies impact 50,000+ global hATTR patients, shifting outcomes from palliative to stabilizing cardiac and neurologic decline (Kristen et al., 2018).

Key Research Challenges

Long-term Safety Monitoring

Patisiran phase II showed TTR silencing but requires extended data on infusion reactions and immunogenicity (Suhr et al., 2015). Thrombocytopenia with inotersen demands platelet monitoring protocols (Benson et al., 2018). Cardiac amyloid progression persists despite TTR reduction (Adams et al., 2018).

Cardiac Outcome Variability

APOLLO trial noted neuropathy gains but inconsistent cardiac stabilization in ATTR-CM subsets (Adams et al., 2018). Expert consensus highlights need for imaging biomarkers beyond TTR levels (Dorbala et al., 2019). Mixed ATTR polyneuropathy and cardiomyopathy responses complicate endpoints (Kristen et al., 2018).

Patient Selection Optimization

Screening guidelines stress early hATTR diagnosis to maximize RNAi benefits before irreversible damage (Witteles et al., 2019). Consensus recommends genetic testing and scintigraphy for polyneuropathy cases (Adams et al., 2020). Heterogeneity in TTR variants affects therapy response (Hawkins et al., 2015).

Essential Papers

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

David Adams, Alejandra González‐Duarte, William O’Riordan et al. · 2018 · New England Journal of Medicine · 2.7K citations

In this trial, patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO ClinicalTrials.gov number, NCT01960348 .).

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

Merrill D. Benson, Márcia Waddington‐Cruz, John L. Berk et al. · 2018 · New England Journal of Medicine · 1.4K citations

Inotersen improved the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis. Thrombocytopenia and glomerulonephritis were managed with enhanced mon...

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging

Sharmila Dorbala, Yukio Ando, Sabahat Bokhari et al. · 2019 · Journal of Nuclear Cardiology · 452 citations

Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis

Christian Nitsche, Paul Scully, Kush Patel et al. · 2020 · Journal of the American College of Cardiology · 338 citations

Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice

Ronald Witteles, Sabahat Bokhari, Thibaud Damy et al. · 2019 · JACC Heart Failure · 323 citations

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, progressive, infiltrative disease caused by the deposition of transthyretin amyloid fibrils in the heart, and can often be over...

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study

Ole B. Suhr, Teresa Coelho, Juan Buades et al. · 2015 · Orphanet Journal of Rare Diseases · 316 citations

NCT01617967 .

Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp> orking <scp>G</scp> roup on <scp>M</scp> yocardial and <scp>P</scp> ericardial <scp>D</scp> iseases

Pablo García‐Pavía, Claudio Rapezzi, Yehuda Adler et al. · 2021 · European Journal of Heart Failure · 315 citations

Abstract Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in th...

Reading Guide

Foundational Papers

No pre-2015 foundational papers available; start with phase II patisiran (Suhr et al., 2015, 316 citations) for dosing and safety basis.

Recent Advances

Adams et al. (2018, 2745 citations) for APOLLO phase III; Benson et al. (2018, 1352 citations) for inotersen; Adams et al. (2020) for diagnostic consensus.

Core Methods

siRNA-lipid nanoparticle delivery for TTR mRNA cleavage; mNIS+7/neuropathy scores; 99mTc-DPD scintigraphy for ATTR-CM; enhanced monitoring for thrombocytopenia.

How PapersFlow Helps You Research RNAi Therapy for Transthyretin Amyloidosis

Discover & Search

Research Agent uses searchPapers and citationGraph on 'patisiran APOLLO trial' to map 2745-citing works from Adams et al. (2018), then exaSearch uncovers vutrisiran analogs. findSimilarPapers links phase II data (Suhr et al., 2015) to inotersen trials.

Analyze & Verify

Analysis Agent applies readPaperContent to extract TTR reduction stats from Adams et al. (2018), verifies claims via CoVe against Benson et al. (2018), and runs PythonAnalysis on GRADE-scored endpoints for neuropathy stabilization (e.g., mNIS+7 scores). Statistical verification confirms 80% TTR knockdown p-values.

Synthesize & Write

Synthesis Agent detects gaps in long-term cardiac data post-patisiran, flags contradictions between polyneuropathy and ATTR-CM outcomes. Writing Agent uses latexEditText, latexSyncCitations for Adams (2018), and latexCompile trial comparison tables; exportMermaid diagrams TTR silencing pathways.

Use Cases

"Extract survival curves and hazard ratios from patisiran APOLLO trial data."

Research Agent → searchPapers('Adams 2018 patisiran') → Analysis Agent → readPaperContent + runPythonAnalysis (pandas/matplotlib plots HRs) → GRADE-verified CSV export.

"Draft LaTeX review comparing patisiran vs inotersen thrombocytopenia risks."

Synthesis Agent → gap detection (safety data) → Writing Agent → latexEditText (intro) → latexSyncCitations (Adams 2018, Benson 2018) → latexCompile PDF.

"Find GitHub repos analyzing TTR gene knockdown simulations from RNAi papers."

Research Agent → citationGraph(Adams 2018) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect (Python RNAi models).

Automated Workflows

Deep Research workflow scans 50+ ATTR papers via searchPapers, structures patisiran/inotersen meta-analysis with GRADE grading. DeepScan's 7-step chain verifies APOLLO cardiac endpoints (readPaperContent → CoVe → runPythonAnalysis). Theorizer generates hypotheses on RNAi resistance from TTR variant data (Hawkins et al., 2015).

Try Doxa for RNAi Therapy for Transthyretin Amyloidosis Research

Frequently Asked Questions

What defines RNAi therapy in transthyretin amyloidosis?

RNAi agents like patisiran use lipid nanoparticles to deliver siRNA silencing hepatic TTR production by 80% in hATTR (Adams et al., 2018).

What are key methods in patisiran trials?

APOLLO phase III used mNIS+7 for neuropathy, Norfolk QoL-DN for quality of life, and 99mTc-PYP scans for cardiac staging (Adams et al., 2018; Suhr et al., 2015).

What are landmark papers?

Adams et al. (2018, NEJM, 2745 citations) proved patisiran efficacy; Benson et al. (2018, NEJM, 1352 citations) validated inotersen; Suhr et al. (2015) provided phase II safety.

What open problems remain?

Long-term cardiac outcomes post-RNAi need clarification; variant-specific responses vary; combination with tafamidis untested (Kristen et al., 2018; Hawkins et al., 2015).